GnuBio Aims for $30 Genome with New Microfluidics Technology | GenomeWeb

Sequencing technology startup company GnuBio has obtained a license from Harvard University to use microfluidics- and emulsion-based technology developed there. These tools will enable the firm to develop a DNA sequencer that can sequence a human genome at 30X coverage — for less than $100 in reagent costs, the company says. GnuBio says the sequencer will also be able to run diagnostic-scale batches across a small candidate gene region at 100X coverage for less than $2 per sample.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.